Issue Date: March 6, 2017
BMS teams with Grail on cancer detection
Bristol-Myers Squibb has undertaken a research collaboration with Grail, a computer-based DNA-sequencing firm specializing in cancer detection, aimed at developing blood tests that detect cancer in early stages. BMS will gain access to the company’s clinical trial database as a resource in understanding tumor genomics. BMS, along with Johnson & Johnson, Celgene, and others, has invested $900 million in Grail’s series B fundraising round. Grail expects to raise more than $1 billion to advance cancer blood testing before the latest round closes.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society